Aytu BioPharma, Inc (AYTU) stock
AYTUNasdaqPharmaceutical PreparationsFiscal year ends June 30
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 9/3070% below fair value
$2.66+0.84 (+46.15%)
Close on Nov 17, 2026Market cap $28.91MP/E –Yield –
Aytu BioPharma r&d expenses
Research and development expenses are spending on new products and technology.
Aytu BioPharma's R&D Expenses for the twelve months ending Jun 30, 2026 was $0, down 100.0% year over year. For fiscal 2026 it was $0, down 100.0% from the year before. The highest annual figure on record is $12.66M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | $0 | -100.0% |
| FY2025 | Jun 30, 2025 | $1.33M | -52.1% |
| FY2024 | Jun 30, 2024 | $2.77M | -32.4% |
| FY2023 | Jun 30, 2023 | $4.10M | -67.7% |
| FY2022 | Jun 30, 2022 | $12.66M | +125.2% |
| FY2021 | Jun 30, 2021 | $5.62M | +226.5% |
| FY2020 | Jun 30, 2020 | $1.72M | +192.3% |
| FY2019 | Jun 30, 2019 | $589.07K | +251.5% |
| FY2018 | Jun 30, 2018 | $167.60K | -82.5% |
| FY2017 | Jun 30, 2017 | $959.86K | -84.3% |
| FY2016 | Jun 30, 2016 | $6.13M | +90.3% |
| FY2015 | Jun 30, 2015 | $3.22M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | $0 | -100.0% |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | $0 | -100.0% |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | $0 | -100.0% |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | $0 | -100.0% |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | $216.00K | -79.3% |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | $162.00K | -73.5% |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | $522.00K | +0.2% |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | $426.00K | -28.4% |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | $1.04M | +124.1% |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | $611.00K | -28.6% |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | $521.00K | -69.5% |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | $595.00K | -44.1% |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | $465.00K | -85.7% |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | $856.00K | -73.9% |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | $1.71M | -61.8% |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | $1.06M | -35.6% |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | $3.25M | -31.7% |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | $3.28M | +741.5% |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | $4.48M | +1464.7% |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | $1.65M | +802.7% |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | $4.76M | +217.9% |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | $390.00K | +396.8% |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | $286.00K | +328.9% |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | $183.00K | +134.6% |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | $1.50M | +755.2% |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | $78.50K | -27.9% |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | $66.68K | -55.3% |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | $78.02K | -49.9% |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | $175.26K | -7.7% |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | $108.90K | -4.6% |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | $149.03K | – |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | $155.88K | +10.6% |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | $189.99K | +2.5% |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | $114.14K | -59.1% |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | -$277.49K | -205.3% |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | $140.95K | -39.2% |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | $185.33K | – |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | $279.05K | – |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | $263.46K | – |
| Q1 FY2017CQ3 2016 | Sep 30, 2016 | $232.02K | – |
See a number that looks wrong?